NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $97.08 +1.48 (+1.55%) Closing price 04:00 PM EasternExtended Trading$97.40 +0.31 (+0.32%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Incyte Stock (NASDAQ:INCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Incyte alerts:Sign Up Key Stats Today's Range$96.04▼$98.4050-Day Range$90.30▼$100.3252-Week Range$63.51▼$112.29Volume1.07 million shsAverage Volume1.70 million shsMarket Capitalization$19.39 billionP/E Ratio13.71Dividend YieldN/APrice Target$104.26Consensus RatingHold Company Overview Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases. The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera. Incyte has expanded its JAK franchise with the topical formulation Opzelura® (ruxolitinib cream), which is approved for atopic dermatitis and vitiligo. Beyond JAK inhibition, the company maintains a deep pipeline that includes programs targeting IDO1, PI3Kδ and PD-1/PD-L1, among other mechanisms, with candidates in various stages of clinical development. Incyte conducts clinical trials and commercial operations across North America, Europe and the Asia-Pacific region. The company has established strategic collaborations and licensing agreements with several global partners to extend its reach and leverage complementary expertise in regulatory affairs, manufacturing and marketing. Leadership at Incyte is headed by President and Chief Executive Officer Hervé Hoppenot, who brings extensive experience in global biopharmaceutical management. Under his stewardship, the company continues to prioritize innovation, rigorous clinical investigation and patient access to new therapies.AI Generated. May Contain Errors. Read More Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 91% of companies evaluated by MarketBeat, and ranked 44th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 10 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Incyte is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageIncyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.95% Earnings GrowthEarnings for Incyte are expected to grow by 17.95% in the coming year, from $6.74 to $7.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 13.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.54.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 13.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.74.Price to Earnings Growth RatioIncyte has a PEG Ratio of 0.91. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.78% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 7.05.Change versus previous monthShort interest in Incyte has recently decreased by 5.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.25 News SentimentIncyte has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Incyte this week, compared to 10 articles on an average week.Search Interest22 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 69% compared to the previous 30 days.MarketBeat Follows8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,560,544.00 in company stock.Percentage Held by Insiders16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCY Stock News HeadlinesIncyte Stock: Analyst Estimates & Ratings34 minutes ago | finance.yahoo.comIncyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 2:00 PM | seekingalpha.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Incyte Stock: Analyst Estimates & RatingsMay 19 at 10:30 AM | barchart.comWells Fargo Remains a Hold on Incyte (INCY)May 14, 2026 | theglobeandmail.comIncyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 13, 2026 | seekingalpha.comIncyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 CongressMay 12, 2026 | businesswire.comIncyte (NASDAQ:INCY) Insider Pablo Cagnoni Sells 18,667 SharesApril 22, 2026 | insidertrades.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $98.77 on January 1st, 2026. Since then, INCY shares have decreased by 1.7% and is now trading at $97.08. How were Incyte's earnings last quarter? Incyte Corporation (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, April, 28th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.38 by $0.43. The business's revenue was up 20.9% compared to the same quarter last year. Read the conference call transcript. Who are Incyte's major shareholders? Top institutional investors of Incyte include Renaissance Technologies LLC (1.83%), Arrowstreet Capital Limited Partnership (1.42%), Dimensional Fund Advisors LP (0.99%) and First Trust Advisors LP (0.75%). Insiders that own company stock include Pablo J Cagnoni, Mohamed Khairie Issa, Steven H Stein, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Lee Heeson, Michael James Morrissey, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings4/28/2026Today5/20/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, INCY's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,844Year Founded1991Price Target and Rating Average Price Target for Incyte$104.26 High Price Target$135.00 Low Price Target$60.00 Potential Upside/Downside+7.4%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)$7.08 Trailing P/E Ratio13.71 Forward P/E Ratio14.40 P/E Growth0.91Net Income$1.29 billion Net Margins26.71% Pretax Margin33.09% Return on Equity26.66% Return on Assets19.77% Debt Debt-to-Equity Ratio0.01 Current Ratio3.68 Quick Ratio3.60 Sales & Book Value Annual Sales$5.36 billion Price / Sales3.62 Cash Flow$6.30 per share Price / Cash Flow15.40 Book Value$28.15 per share Price / Book3.45Miscellaneous Outstanding Shares199,782,000Free Float167,417,000Market Cap$19.39 billion OptionableOptionable Beta0.79 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:INCY) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
